Medigen Vaccine Biologics Corp.(TW:6547)
NT$46.35-5.15 (-10.00%)
TW:6547
Medigen Vaccine Biologics Corp. financials statements
NT$46.35
At close:-5.15 (-10.00%)
Medigen Vaccine Biologics Corp. (6547) Ratios
Medigen Vaccine Biologics Corp. Ratios
TW:6547's free cash flow for Q2 2026 was NT$-123.92M. For the 2026 fiscal year, TW:6547's free cash flow was decreased by NT$-32.72M and operating cash flow was NT$-91.20M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 12.77 | 11.94 | 2.21 | 15.38 | 8.47 |
| Quick Ratio | 10.64 | 9.83 | 2.02 | 13.84 | 7.19 |
| Cash Ratio | 3.20 | 3.34 | 0.70 | 3.39 | 3.14 |
| Solvency Ratio | -0.31 | 0.11 | -0.46 | -0.59 | 2.44 |
| Operating Cash Flow Ratio | -0.27 | 0.19 | -0.24 | -3.10 | 1.32 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 1.76 | -0.28 | -1894.94 | 335.19 |
| Net Current Asset Value | NT$ 1.91B | NT$ 2.04B | NT$ 2.16B | NT$ 3.14B | NT$ 3.10B |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.07 | 0.08 | 0.32 | 0.27 | 0.04 |
| Debt-to-Equity Ratio | 0.08 | 0.09 | 0.51 | 0.39 | 0.04 |
| Debt-to-Capital Ratio | 0.08 | 0.08 | 0.34 | 0.28 | 0.04 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.25 | 0.00 |
| Financial Leverage Ratio | 1.13 | 1.13 | 1.58 | 1.46 | 1.13 |
| Debt Service Coverage Ratio | -14.08 | 1.78 | -0.57 | -49.03 | 196.52 |
| Interest Coverage Ratio | -30.19 | -7.71 | -32.31 | -53.84 | 235.30 |
| Debt to Market Cap | 0.00 | 0.00 | 0.07 | 0.08 | 0.00 |
| Interest Debt Per Share | 0.89 | 1.09 | 6.13 | 6.19 | 0.61 |
| Net Debt to EBITDA | 2.49 | -5.03 | -0.59 | -0.58 | -0.78 |
| Profitability Margins | |||||
| Gross Profit Margin | 59.47% | 65.46% | 59.09% | -58.24% | 70.25% |
| EBIT Margin | -43.33% | -10.17% | -288.04% | -396.58% | 29.37% |
| EBITDA Margin | -20.21% | 12.36% | -254.37% | -361.55% | 46.60% |
| Operating Profit Margin | -43.33% | -24.05% | -311.54% | -396.58% | 43.17% |
| Pretax Profit Margin | -45.94% | -13.29% | -297.68% | -403.95% | 42.98% |
| Net Profit Margin | -45.94% | -13.29% | -297.68% | -411.31% | 42.98% |
| Continuous Operations Profit Margin | -45.94% | -13.29% | -297.68% | -403.95% | 42.98% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 101.82% | 100.00% |
| EBT Per EBIT | 106.03% | 55.24% | 95.55% | 101.86% | 99.58% |
| Return on Assets (ROA) | -7.16% | -1.84% | -19.04% | -20.43% | 26.61% |
| Return on Equity (ROE) | -8.10% | -2.09% | -30.15% | -29.86% | 30.16% |
| Return on Capital Employed (ROCE) | -7.09% | -3.51% | -29.60% | -20.70% | 29.14% |
| Return on Invested Capital (ROIC) | -7.06% | -3.48% | -20.85% | -20.67% | 29.00% |
| Return on Tangible Assets | -7.20% | -1.86% | -19.16% | -20.56% | 26.88% |
| Earnings Yield | -2.28% | -0.68% | -5.04% | -6.68% | 2.22% |
| Efficiency Ratios | |||||
| Receivables Turnover | 4.30 | 4.73 | 1.96 | 1.87 | 5.12 |
| Payables Turnover | 23.45 | 15.63 | 6.16 | 5.32 | 11.24 |
| Inventory Turnover | 0.63 | 0.46 | 0.42 | 1.06 | 1.73 |
| Fixed Asset Turnover | 0.49 | 0.45 | 0.28 | 0.25 | 2.32 |
| Asset Turnover | 0.16 | 0.14 | 0.06 | 0.05 | 0.62 |
| Working Capital Turnover Ratio | 0.27 | 0.25 | 0.10 | 0.09 | 1.28 |
| Cash Conversion Cycle | 647.64 | 842.47 | 1005.46 | 471.21 | 249.50 |
| Days of Sales Outstanding | 84.85 | 77.15 | 186.28 | 195.55 | 71.23 |
| Days of Inventory Outstanding | 578.35 | 788.67 | 878.45 | 344.24 | 210.74 |
| Days of Payables Outstanding | 15.56 | 23.36 | 59.27 | 68.57 | 32.46 |
| Operating Cycle | 663.20 | 865.82 | 1064.73 | 539.79 | 281.97 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.15 | 0.12 | -1.46 | -3.40 | 1.84 |
| Free Cash Flow Per Share | -0.30 | 0.02 | -1.58 | -3.84 | 1.41 |
| Dividend Paid and CapEx Coverage Ratio | -0.97 | 1.17 | -11.68 | -7.84 | 4.30 |
| Capital Expenditure Coverage Ratio | -0.97 | 1.17 | -11.68 | -7.84 | 4.30 |
| Operating Cash Flow Coverage Ratio | -0.17 | 0.12 | -0.24 | -0.56 | 3.09 |
| Operating Cash Flow to Sales Ratio | -0.08 | 0.07 | -1.23 | -3.02 | 0.18 |
| Free Cash Flow Yield | -0.81% | 0.05% | -2.26% | -5.52% | 0.70% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -43.90 | -150.21 | -19.86 | -14.98 | 44.95 |
| Price-to-Sales (P/S) Ratio | 20.17 | 19.56 | 59.07 | 61.59 | 19.32 |
| Price-to-Book (P/B) Ratio | 3.55 | 3.08 | 5.98 | 4.47 | 13.56 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -124.00 | 2052.16 | -44.32 | -18.11 | 142.48 |
| Price-to-Operating Cash Flow Ratio | -251.92 | 290.71 | -48.11 | -20.42 | 109.32 |
| Price-to-Earnings Growth (PEG) Ratio | -0.17 | 1.61 | 0.83 | 0.07 | -0.16 |
| Enterprise Value Multiple | -97.31 | 153.22 | -23.81 | -17.62 | 40.69 |
| Enterprise Value | 12.06B | 11.47B | 23.60B | 23.25B | 62.20B |
| EV to EBITDA | -97.31 | 153.22 | -23.81 | -17.62 | 40.69 |
| EV to Sales | 19.66 | 18.94 | 60.56 | 63.70 | 18.96 |
| EV to Free Cash Flow | -120.91 | 1986.92 | -45.44 | -18.73 | 139.80 |
| EV to Operating Cash Flow | -245.63 | 281.46 | -49.33 | -21.12 | 107.27 |
| Tangible Book Value Per Share | 10.56 | 11.63 | 11.60 | 15.41 | 14.65 |
| Shareholders’ Equity Per Share | 10.62 | 11.72 | 11.72 | 15.55 | 14.82 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | -0.02 | 0.00 |
| Revenue Per Share | 1.87 | 1.84 | 1.19 | 1.13 | 10.40 |
| Net Income Per Share | -0.86 | -0.24 | -3.53 | -4.64 | 4.47 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.02 | 1.00 |
| Interest Burden | 1.06 | 1.31 | 1.03 | 1.02 | 1.46 |
| Research & Development to Revenue | 0.54 | 0.37 | 3.08 | 3.12 | 0.36 |
| SG&A to Revenue | 0.40 | 0.53 | 0.62 | 0.50 | 0.05 |
| Stock-Based Compensation to Revenue | 0.05 | 0.02 | 0.05 | 0.21 | 0.02 |
| Income Quality | 0.17 | -0.51 | 0.41 | 0.75 | 0.41 |
Currency in TWD
